Market Overview:
Epilepsy is a neurological disorder that affects people of all ages. It is characterized by recurrent seizures, which are sudden bursts of electrical activity in the brain. Epilepsy drugs are used to control seizures. The global epilepsy drug market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The global epilepsy drug market can be segmented by type, application and region. By type, the market can be divided into first generation drugs, second generation drugs and third generation drugs. First generation drugs include phenobarbital and primidone while second generation drugs include valproate semisodium (valproic acid) and carbamazepine (Tegretol).
Product Definition:
Epilepsy Drug is a medication used to prevent and control seizures. It is important for people with epilepsy to take their medication as prescribed in order to reduce the risk of seizure.
First Generation Drugs:
First generation antiepileptic drugs include phenobarbital, carbamazepine, and valproate. These are used to treat seizures associated with epilepsy. Epilepsy is a neurological disorder in which there are frequent and prolonged seizures. The incidence of this disease is estimated at 50-100 per million people annually globally (range: 25-50 per million in North America; 10-25 per million in Europe).
Second Generation Drugs:
Second generation drugs are a new class of antiepileptic drugs, which were introduced in the market after first-generation (1G) antiepileptics. These are more effective and have fewer side effects. The major difference between 1G and 2G drugs is that the latter ones do not cause drowsiness whereas the former ones do.
The global epilepsy drug market was valued at USD 4,000 million in 2012.
Application Insights:
Based on the application, the global epilepsy drug market is segmented into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to a large patient base with epilepsy and increasing awareness about treatment options. According to WHO, around 50 million people are living with epilepsy worldwide. Epilepsy affects 0.5% to 2% of adults according to different studies conducted globally which translates into over 2 million individuals in Europe alone as per ECPMB estimates published in 2018.
The growing prevalence of epilepsy coupled with rising awareness levels among patients is expected fuel demand for drugs across all application segments during the forecast period especially for second generation anti-epileptic drugs (AEDs).
Regional Analysis:
North America dominated the global epilepsy drug market in 2017. The high prevalence of the disease and quick adoption of technologically advanced products are some factors responsible for its large share. In addition, favorable government initiatives to raise awareness about epilepsy treatment methods and increase access to healthcare services are expected to drive growth during the forecast period. For instance, in May 2018, Cephalon Inc., a U.S.-based company launched two new drugs that are approved only for use as add-on therapy with existing medication rather than as monotherapy for partial or generalized seizures in adults: Nitrofast and Zarontin respectively (ref).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income levels coupled with increasing prevalence of epilepsy among children & adolescents (0-19 years) across various countries such as India, China & Japan which is anticipated would boost market demand during this period (ref).
Growth Factors:
- Increasing incidence of epilepsy
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective drugs to treat epilepsy
- Technological advancements in the field of epilepsy drug development 5. Availability of government funding for research on new epilepsy drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Epilepsy Drug Market Research Report
By Type
First Generation Drugs, Second Generation Drugs, Third Generation Drugs
By Application
Hospital, Clinic, Others
By Companies
Pfizer, Eisai, Novartis, Sanofi, Union Chimique Belge, Abbott, GlaxoSmithKline, Sunovion Pharmaceuticals, Teva Pharmaceutical, Johnson & Johnson, Pfizer, Janssen Pharmaceuticals, Cephalon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
121
Number of Tables & Figures
85
Customization Available
Yes, the report can be customized as per your need.
Global Epilepsy Drug Market Report Segments:
The global Epilepsy Drug market is segmented on the basis of:
Types
First Generation Drugs, Second Generation Drugs, Third Generation Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Eisai
- Novartis
- Sanofi
- Union Chimique Belge
- Abbott
- GlaxoSmithKline
- Sunovion Pharmaceuticals
- Teva Pharmaceutical
- Johnson & Johnson
- Pfizer
- Janssen Pharmaceuticals
- Cephalon
Highlights of The Epilepsy Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- First Generation Drugs
- Second Generation Drugs
- Third Generation Drugs
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Epilepsy Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Epilepsy drug is a medication used to treat epilepsy.
Some of the major players in the epilepsy drug market are Pfizer, Eisai, Novartis, Sanofi, Union Chimique Belge, Abbott, GlaxoSmithKline, Sunovion Pharmaceuticals, Teva Pharmaceutical, Johnson & Johnson, Pfizer, Janssen Pharmaceuticals, Cephalon.
The epilepsy drug market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Epilepsy Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Epilepsy Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Epilepsy Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Epilepsy Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Epilepsy Drug Market Size & Forecast, 2020-2028 4.5.1 Epilepsy Drug Market Size and Y-o-Y Growth 4.5.2 Epilepsy Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 First Generation Drugs
5.2.2 Second Generation Drugs
5.2.3 Third Generation Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Epilepsy Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Epilepsy Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 First Generation Drugs
9.6.2 Second Generation Drugs
9.6.3 Third Generation Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 First Generation Drugs
10.6.2 Second Generation Drugs
10.6.3 Third Generation Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 First Generation Drugs
11.6.2 Second Generation Drugs
11.6.3 Third Generation Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 First Generation Drugs
12.6.2 Second Generation Drugs
12.6.3 Third Generation Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 First Generation Drugs
13.6.2 Second Generation Drugs
13.6.3 Third Generation Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Epilepsy Drug Market: Competitive Dashboard
14.2 Global Epilepsy Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Eisai
14.3.3 Novartis
14.3.4 Sanofi
14.3.5 Union Chimique Belge
14.3.6 Abbott
14.3.7 GlaxoSmithKline
14.3.8 Sunovion Pharmaceuticals
14.3.9 Teva Pharmaceutical
14.3.10 Johnson & Johnson
14.3.11 Pfizer
14.3.12 Janssen Pharmaceuticals
14.3.13 Cephalon